You are here

Adapting wireless glucometer to boost opioid dependence medication compliance

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43TR000616-01
Agency Tracking Number: R43TR000616
Amount: $150,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCATS
Solicitation Number: PA12-088
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
7 Tide St.
Boston, MA 02210-
United States
DUNS: 827811626
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (814) 422-5362
Business Contact
Phone: (814) 422-5362
Research Institution

DESCRIPTION: Plant-derived secondary metabolites have proven to be a rich source of pharmaceuticals. From 1981 to 2010, over 65% of the 1355 new chemical entities introduced worldwide were natural products or natural product derivatives. The benzylisoquinoline alkaloids (BIAs) represent a diverse class of secondary metabolites (2500 known structures) with a broad range of pharmacological activities. Efforts to develop new chemical entities sourced or derived from plant secondary metabolites have largely faltered, because (a) the complexity and stereochemistry of natural products is difficult to access via synthetic chemistry and (b) the yiel of natural products extracted directly from plants can be insufficient to capture the full range of natural productspresent in a particular species. The goal of our Phase I work is to do a proof-of-concept demonstration that we can (a) make a microbial chassis for the production of the BIA key intermediate (S)-reticuline based on the naturally occurring pathway found in some plants and (b) show that the chassis can be used to make a small set of BIAs derived from reticuline. Future effort will be based on this BIA chassis strain and will focus on the development of specialized strains targeting a particular molecule ornatural product scaffold. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Plants have proven to be a rich source of pharmaceuticals with natural products or natural product derivatives representing over 65% of pharma compounds developed in the past 30 years. Often these natural products are found in quantities too small for meaningful study. In order to expand the library of prospective compounds, we are developing microbial strains that produce a broad range of plant alkaloid natural products(over 2500 members) that are relevant for treating infections, inflammation, chronic pain, Parkinson's disease, and likely have other yet unknown uses.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government